Glenmark intros generic Banzel
Banzel tablets had a market value of $285.3 million for the 12-month period ended April 2021, according to IQVIA.
Glenmark is offering rufinamide tablets in dosage strengths of 200 mg and 400 mg.
The product is the first generic of Eisai’s Banzel.
“We are very pleased to be one of the first generic companies in the United States to offer lower cost alternative to Banzel tablets, 200 mg and 400 mg.,” said Sanjeev Krishan, Glenmark North America president. “The launch is our commitment to provide quality and affordable healthcare to our markets for patients.”
Banzel tablets had a market value of $285.3 million, for the 12-month period ended April 2021, according to IQVIA.